Prostate cancer a pathophysiology gaw hpa rai kun?
Prostate cancer a pathophysiology ngu ai gaw, ana byin wa ai lam hte rawt jat wa ai lam hpe chye lu ai.
Prostate cancer ngu ai gaw, la ni a kan kata kaw nga ai, nlung hkrang hte bung ai, prostate gland ngu ai, n gup ganghkau a npu kaw na byin pru wa ai, n kaja ai ana rai nga ai.
Lawu shakum gaw, la chyu hpe shahpa jaw nna, htaw shalai ya ai la chyu hpe shapraw ya ai.
Dai hta n-ga, sai rawt ai lam hta mung, sai n shang yang, sai n kap ai lam hta mung, sai n kap ai lam hta mung, sai n kap ai lam hta mung, sai n kap ai lam hta mung, sai n kap ai lam hta mung, sai n kap ai lam hta mung, sai n kap ai lam hta mung, sai n kap ai lam hta mung, sai n kap ai lam hta mung lawm ai.
Dai hta asak, dinghku labau, amyu baw sang hte nkau mi a aru arat galai shai ai lam ni lawm ai.
Prostat cancer gaw asak kaba sai la ni hta grau byin ai rai nna, dai hta na malawng gaw asak 65 ning jan ai la ni re.
Dai hta n-ga, shan chyang ana byin ai lam, shan a nta masha ni hta byin wa ai lam, African American ni hte Caribbean amyu ni hta byin wa ai lam ni mung lawm ai.
Prostate cancer a pathophysiology hta prostate gland kata na cell ni n hkang lu ai hku kaba wa ai hte garan wa ai lam lawm ai.
Dai gaw, byin wa ai lam ni hta, byin wa ai lam ni hpe n chye lu ai majaw re.
Dai zawn galai shai ai lam ni gaw, hkum hkrang hta ana byin wa hkra galaw ya ai.
Dai ana kaba wa ai hte rau, makau grup yin na sai hte daw shan ni hpe mung shang wa lu ai.
Nkau mi hta, cancer cell ni gaw, shawng nnan byin ai tumor kaw nna, sai lam (sh) lymphatic system hku nna, hkum hkrang a kaga daw de chyam bra wa chye ai.
Dai hta n-ga, ana gaw grau nna galu wa yang, tsi lajang na matu grau yak wa ai.
Prostate cancer hpe hormone ni, grau nna androgen hormone testosterone ni mung byin shangun ai.
Testosterone gaw prostate cancer cell ni rawt jat wa hkra galaw ya lu ai. Dai majaw, prostate cancer hpe tsi ai lam law law gaw, ndai hormone hpe yawm shangun ai (sh) dai hpe n galaw shangun ai hku galaw ai.
Dai majaw, prostate cancer a pathophysiology gaw, prostate gland kata hta n hkang lu ai hku nna, cell ni kaba wa nna, garan wa ai lam re.
Ana a npawt nhpang hpe chye na lu ai gaw, ana hpe atsawm tsi lajang lu na matu hte, prostate cancer ana lu ai ni a hkamja lam hpe grau kaja hkra galaw lu na matu ahkyak ai.
Zobniw CM, Causebrook A, Fong MK: Clinical use of abiraterone in the treatment of metastatic castration-resistant prostate cancer. Res Rep Urol. 2014, 6 (): 97-105.
Lim HY, Agarwal AM, Agarwal N, Ward JH: Recurrent epistaxis as a presenting sign of androgen-sensitive metastatic prostate cancer. Singapore Med J. 2009, 50 (5): e178-80.
Kohli M, Qin R, Jimenez R, Dehm SM: Biomarker-based targeting of the androgen-androgen receptor axis in advanced prostate cancer. Adv Urol. 2012, 2012 (): 781459.
Nelson JB, Hedican SP, George DJ, Reddi AH, Piantadosi S, Eisenberger MA, Simons JW: Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate. Nat Med. 1995, 1 (9): 944-9.
Msaouel P, Nandikolla G, Pneumaticos SG, Koutsilieris M: Bone microenvironment-targeted manipulations for the treatment of osteoblastic metastasis in castration-resistant prostate cancer. Expert Opin Investig Drugs. 2013, 22 (11): 1385-400.
Kotani K, Sekine Y, Ishikawa S, Ikpot IZ, Suzuki K, Remaley AT: High-density lipoprotein and prostate cancer: an overview. J Epidemiol. 2013, 23 (5): 313-9.
Jadvar H: Molecular imaging of prostate cancer: a concise synopsis. Mol Imaging. , 8 (2): 56-64.
['N hkap la ai lam: tsi mawan']
['Ndai website gaw hpaji jaw ai hte chye na matu sha galaw da ai.']
['Ndai laika buk hta lawm ai lam ni hpe hkamja lam hte seng nna, ana jep ai (sh) tsi ai lam hta n mai jai lang ai.']
['Ga san ni a mahtai hpe shapraw ya ai neural net gaw, ga shadawn, masha langai ngai hta ana langai ngai mu lu ai lam ni hpe madun ai shaloi, n hkrak ai.']
['Ndai website hta mu lu ai lam ni a majaw, tsi sarawun ni a hpaji jaw ga hpe galoi mung n madat ai sha, hpang hkrat ai lam n galaw u. Tsi hte seng nna, ra kadawn nga ai lam nga yang, 911 hpe shaga u. Ndai website hte dai hpe lang ai lam gaw, tsi sarawun hte machyi masha lapran hku hkau lam n nga ai. BioMedLib hte shi a bungli galaw masha ni, ndai website hta shang lawm ai ni kadai mung, ndai kaw lawm ai shiga hte seng nna, tsun mayu ai lam (sh) tsun ai hku nna, hpa ga sadi jaw ai lam n nga ai.']
['Hti na ahkang n nga ai: copyright']
['1998 ning Digital Millennium Copyright Act, 17 U.S.C. § 512 (the DMCA) gaw Internet kaw mara da ai lam ni gaw US copyright law npu na madu a ahkaw ahkang hpe tawt lai ai ngu kam ai copyright madu ni hpe ahkaw ahkang jaw da ai.']
['Anhte a website hte seng nna, (sh) anhte a magam bungli ni hte seng nna, mara shagun da ai lam ni gaw, na a copyright hpe tawt lai ai ngu nna nang kam ai nga yang, dai lam ni hpe dawm kau na matu (sh) dai ni hpe n mai lu hkra pat kau na matu, nang (sh) na a kasa gaw anhte hpe shana mai ai.']
['Dai shiga ni hpe laika hte ka nna email hte shagun ra ai (email address hpe "Contact" daw kaw mu lu na re).']
['Dai DMCA gaw, na a copyright tawt lai ai lam hpe shana ai hta lawu na lam ni lawm ra ai: (1) tawt lai ai ngu ai copyright lu ai bungli a lam; (2) tawt lai ai ngu ai lam hte seng ai lam hte dai hpe mu tam lu na matu anhte hpe karum ya ai lam; (3) na a matut mahkai lam, na a shara, phone number hte email hte seng ai lam ni; (4) nang mara shagun ai lam gaw copyright madu, shi a agent (sh) tara upadi hte n seng ai ngu ai hpe nang kam ai lam.']
['(5) N teng n man ai sakse hkam ai lam hte seng nna, nang masat da ai hte maren, shana ai lam hta lawm ai shiga ni gaw teng man ai hte, nang tawt lai ai ngu ai copyright hpe hkan sa na ahkang nga ai lam.']
['hte (6) copyright madu a mying hte galaw na ahkang lu ai wa a hkum hkrang (sh) electronic signature.']
['Lahta na lam ni hpe n ka bang ai rai yang, nang shagun ai laika hpe hpang hkrat ai hte n mai htang ai.']
['Matut Mahkai U']
['Gara hku mung san mayu yang email hte shana ya rit.']
What is pathophysiology of prostate cancer?
The pathophysiology of prostate cancer refers to the underlying mechanisms and processes that lead to the development and progression of the disease.
Prostate cancer is a malignant tumor that arises from the cells of the prostate gland, which is a small, walnut-shaped organ located below the bladder in men.
The prostate gland produces seminal fluid, which nourishes and transports sperm.
The exact cause of prostate cancer is not fully understood, but several factors are known to increase the risk of developing the disease.
These include age, family history, race, and certain genetic mutations.
Prostate cancer is more common in older men, with the majority of cases occurring in men over the age of 65.
Additionally, men with a family history of prostate cancer are at an increased risk, as are African American men and men of Caribbean descent.
The pathophysiology of prostate cancer involves the uncontrolled growth and division of cells within the prostate gland.
This can occur due to genetic mutations that lead to the overexpression of certain growth factors or the inactivation of tumor suppressor genes.
These mutations can result in the unregulated growth of cells, leading to the formation of a tumor.
As the tumor grows, it can invade nearby tissues and organs, such as the bladder, rectum, and nearby lymph nodes.
In some cases, cancer cells can break away from the primary tumor and spread to other parts of the body through the bloodstream or lymphatic system, a process known as metastasis.
Once the cancer has spread, it can be more difficult to treat.
Prostate cancer can also be influenced by hormonal factors, particularly the androgen hormone testosterone.
Testosterone can stimulate the growth of prostate cancer cells, and many treatments for prostate cancer aim to reduce the levels of this hormone or block its effects.
In summary, the pathophysiology of prostate cancer involves the uncontrolled growth and division of cells within the prostate gland, which can be influenced by genetic, hormonal, and environmental factors.
Understanding the underlying mechanisms of the disease is crucial for developing effective treatments and improving outcomes for patients with prostate cancer.
Disclaimer: medical
This web site is provided for educational and informational purposes only and does not constitute providing medical advice or professional services.
The information provided should not be used for diagnosing or treating a health problem or disease, and those seeking personal medical advice should consult with a licensed physician.
Please note the neural net that generates answers to the questions, is specially inaccurate when it comes to numeric content. For example, the number of people diagnosed with a specific disease.
Always seek the advice of your doctor or other qualified health provider regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. If you think you may have a medical emergency, call 911 or go to the nearest emergency room immediately. No physician-patient relationship is created by this web site or its use. Neither BioMedLib nor its employees, nor any contributor to this web site, makes any representations, express or implied, with respect to the information provided herein or to its use.
Disclaimer: copyright
The Digital Millennium Copyright Act of 1998, 17 U.S.C. § 512 (the “DMCA”) provides recourse for copyright owners who believe that material appearing on the Internet infringes their rights under U.S. copyright law. If you believe in good faith that any content or material made available in connection with our website or services infringes your copyright, you (or your agent) may send us a notice requesting that the content or material be removed, or access to it blocked. Notices must be sent in writing by email (see 'Contact' section for email address) . The DMCA requires that your notice of alleged copyright infringement include the following information: (1) description of the copyrighted work that is the subject of claimed infringement; (2) description of the alleged infringing content and information sufficient to permit us to locate the content; (3) contact information for you, including your address, telephone number and email address; (4) a statement by you that you have a good faith belief that the content in the manner complained of is not authorized by the copyright owner, or its agent, or by the operation of any law; (5) a statement by you, signed under penalty of perjury, that the information in the notification is accurate and that you have the authority to enforce the copyrights that are claimed to be infringed; and (6) a physical or electronic signature of the copyright owner or a person authorized to act on the copyright owner’s behalf. Failure to include all of the above information may result in the delay of the processing of your complaint.
['Hkrang']
['BioMedLib gaw ga san hte mahtai yan hpe shapraw na matu computer (machine-learning algorithms) ni hpe lang ai.']
['Anhte gaw PubMed/Medline kaw na tsi hpaji hte seng ai laika buk wan 35 hte hpang ai. RefinedWeb kaw na mung re.']
